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Abstract 
The production of superoxide anion by NADPH oxidase is a principal nonspecific bactericidal ctivity of macrophages and neutrophils 
in host defense. However, exuberant production of superoxide anion also damages host tissues. Cloning and DNA sequencing of the 91 
kDa subunit (gp91-phox) open reading frame indicated ahigh degree of sequence conservation, greater than 90% in nucleotide and amino 
acid sequences, between the porcine and human cDNAs. We show in pigs that interleukin-4 (IL-4), a T lymphocyte cytokine which plays 
a major role in mediating antibody responses to pathogens, uppresses superoxide anion production in macrophages by specifically 
reducing the level of mRNA encoding p91-phox. Messenger RNA levels are suppressed approx. 70% within 4 h and persist for 24 h 
without any change in the rate of mRNA turnover. Nuclear run-on analysis howed that IL-4 did not alter the rate of gp91-phox gene 
transcription under conditions in which IL-1/3 transcription was inhibited. These results indicate that IL-4 suppresses the inflammatory 
response of macrophages by mechanisms that include post-transcriptional regulation of the 91 kDa catalytic subunit of NADPH oxidase, 
and transcriptional regulation of inflammatory cytokine expression. 
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1. Introduction 
Macrophages play a central role in host protection by 
initiating inflammatory and immune reactions against bac- 
terial pathogens. They elicit an innate, non-specific inflam- 
matory response by producing inflammatory cytokines and 
toxic oxygen radicals. The production of toxic oxygen 
radicals including superoxide anion (O 2) is an important 
mechanism of microbial killing by macrophages. 
Formation of superoxide anion is catalyzed by a mem- 
brane-associated nzyme system, NADPH oxidase, which 
is an electron transport, multicomponent complex consist- 
ing of several membrane-bound and cytosolic subunits 
[1-3]. The membrane-bound component of NADPH oxi- 
dase, also known as cytochrome b, is a heterodimer con- 
sisting of 91 kDa glycoprotein heavy chain (gp91-phox) 
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and 22 kDa polypeptide light chain (p22-phox) subunits 
[4,5]. It has been shown that the membrane components of 
NADPH oxidase can be activated by chemoattractants, the
tumor promoter phorbol myristate acetate (PMA), or the 
calcium ionophore A23187 [6]. Recent studies revealed 
that human macrophages and neutrophils treated with in- 
terferon (IFN)-7, tumor necrosis factor-a (TNF) and the 
bacterial cell wall product, lipopolysaccharide (LPS), can 
be induced to express increased levels of gp91-phox pro- 
tein and mRNA [7-12]. 
Although important for microbicidal activity, an in- 
creasing body of evidence indicates that free radicals 
derived from oxygen, including superoxide anion, play a 
role in mediating tissue damage and inflammatory diseases 
either directly or indirectly through the generation of other 
inflammatory mediators [13-16]. Superoxide anion causes 
lung tissue damage both in vivo and vitro in human and 
animal models [17-21]. In addition, various clinical disor- 
ders and inflammatory diseases, including inflammatory 
bowel disease [22], acute pancreatitis [23], renal diseases 
such as glomerulonephritis and vasculitis [24], skin inflam- 
mation [25], acalculous cholecystitis [26] and uveitis [27], 
Y. Zhou et aL / Biochimica et Biophysica Acta 1265 (1995) 40-48 41 
are associated with aberrant or over-production f superox- 
ide anion or other reactive oxygen intermediates. More- 
over, recent studies on HIV induction of superoxide anion 
generation suggest an important role in AIDS disease 
progression [28]. 
Interleukin-4, also known as B cell stimulatory factor-1 
(BCSF-1) or B cell growth :factor (BCGF), is a 20 kDa 
protein produced by activated TH2 cells which activates 
the resting B cell to proliferate and increases markedly the 
production of antibodies [29,30]. In addition to its stimulat- 
ing properties, however, an increasing body of evidence 
shows that IL-4 possesses anti-inflammatory effects on 
monocytes and macrophages. It has been shown to down- 
regulate the expression and secretion of IL-1, IL-6, IL-8 
and TNF in human and porcine monocytes and 
macrophages stimulated with IFN-y or LPS [31-36]. 
The observations that IL-4 suppresses the induction of 
inflammatory cytokine expression and the production of 
superoxide anion suggests that IL-4 is an important nega- 
tive regulator of macrophage inflammatory activities. We 
were therefore interested in determining if IL-4 suppressed 
superoxide anion production at the transcriptional level 
similar to its effect on inflammatory c tokine levels. We 
found that IL-4 suppresses superoxide anion production in 
porcine alveolar macrophages by reducing the level of 
gp91-phox mRNA posttranscriptionally without affecting 
mRNA stability. 
2. Materials and methods 
2.1. Reagents 
Human recombinant IL-4 and porcine recombinant 
TGF/31 were obtained from R & D Systems (Minneapolis, 
MN). 
2.2. Alveolar macrophages 
Alveolar macrophages were collected by lung lavage 
from normal 6-8-week-old pigs. Cells were ~vashed with 
endotoxin-free PBS and cultured in DMEM with 2% pig 
serum and antibiotics. The cells were allowed to incubated 
at 37°C with 5% CO 2 overnight before treatment. 
2.3. Probes 
The human gp91-phox eDNA probe used for screening 
of a cDNA library was a 1.8 kb XhoI fragment cloned into 
pCDM-8 and was kindly provided by Dr. Stephen Chanock 
(The Children's Hospital, Boston, MA). The porcine p22- 
phox cDNA was a 786 bp fragment containing the com- 
plete 576 bp coding sequence cloned in our laboratory 
(GenBank accession umber UO2477). fl-Actin was a 706 
bp cDNA cloned by reverse transcriptase-polymerase chain 
reaction amplification of porcine fibroblast mRNA 
(GenBank accession umber U07786). Glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) was a 1.25 kb PstI 
fragment of human GAPDH eDNA and was kindly pro- 
vided by Dr. William A. Toscano (Tulane University, New 
Orleans, LA). All probes were labeled with [32p]dCTP 
(Amersham, 3000 Ci/mmol) by random hexanucleotide 
priming to a specific activity of 0.5-1.0 • 10 9 cpm//~g. 
2.4. cDNA library construction and screening 
A porcine macrophage cDNA library was constructed in
hgtl0 by Clontech (Palo Alto, CA) using mRNA from 
porcine alveolar macrophages stimulated with LPS. Ap- 
proximately 100000 plaques were screened with a 32p_ 
labeled human gp91-phox eDNA probe. Two positive 
clones were identified by screening. One clone (A90A) 
was further analyzed by restriction digestion with EcoRI. 
Two restriction fragments of 1.6 kb and 0.7 kb were 
observed upon digestion. The 1.6 kb EcoRI fragment was 
isolated and subcloned into pGEM3Zf(-) plasmid and 
subjected to DNA sequencing. 
2.5. PCR for 5'-end cloning 
PCR primers to amplify the 5'-end of the porcine gp91- 
phox cDNA coding region were designed based on pub- 
lished human gp91-phox cDNA sequence and synthesized 
on an Applied Biosystems 391 DNA synthesizer. Reverse 
transcription-PCR was performed as described in Perkin- 
Elmer's RNA PCR kit with modifications. Briefly, total 
cellular RNA was isolated from pig alveolar macrophages 
stimulated with LPS and reverse transcribed into eDNA 
with oligo dT priming. The eDNA was denatured at 94°C 
for 4 min followed by 30 cycles of amplification in a 25 
/xl volume, with each cycle consisting of 93°C for 30 s, 
55°C for 30 s and 72°C for 30 s. The amplified fragment 
was purified on a SpinBind column (FMC BioProducts, 
Rockland, ME) and was cloned into pGEM3Zf(-) for 
sequencing. 
2.6. DNA sequencing and computer analysis 
DNA sequencing was performed using the dideoxy- 
termination method [37] with vector-derived sequencing 
primers and nested internal specific oligonucleotide 
primers. Double stranded DNA templates were used for all 
of the reactions and were sequenced in both directions. 
Sequence analyses were performed with Intelligenetics and 
Eugene software packages at the Molecular Biology Com- 
puting Center and Department ofMicrobiology, University 
of Minnesota. 
2.7. Superoxide assay 
Superoxide production was quantified by measuring the 
superoxide dismutase (SOD)-inhibitable r duction of ferri- 
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cytochrome C as described by Peterson et al. [38]. 
Macrophages (1.5 • l0 s cells/well) were plated in 96-well 
plates and treated with IL-4 at various concentration for 24 
h. Medium was removed and 120 /xl of Hank's balanced 
salt solution containing 0.1% gelatin (GHBSS) alone or 
GHBSS containing 60 U SOD was added. Eighty /xl of 80 
/xM ferricytochrome C with or without 200 nM PMA in 
GHBSS was added and the plates were incubated at 37°C 
for 30 min. Absorbance was read at A550 on a Perkin-Elmer 
Automated MicroPlate Reader. The amount of O~ release 
was calculated from the formula: 
O2/wel l  = absorbance- 15.87. 107/1.5 • 105 
and expressed as nmol/107cells/30 rain [39]. 
2.8. Northern blot 
Macrophage total cellular RNA was purified by acid- 
guanidinium-phenol extraction as described [40]. Northern 
blot assays were performed according to standard proce- 
dures [41] with the following modifications. Briefly, 20/xg 
of total cellular RNA was electrophoresed in a 1% agarose 
gel containing formaldehyde and transferred onto Magna- 
Graph nylon membranes (MSI, Westborough, MA), in 
20 X SSC (1 X SSC contains 150 mM NaCI and 15 mM 
sodium citrate). Membranes were pre-incubated at 42°C 
for 1 h in a hybridization buffer containing 1 mM EDTA, 
0.5 M sodium phosphate (pH 7.2) and 7% SDS, then 
hybridized for 16-24 h at 42°C with the 32 P-labeled cDNA 
probes. After hybridization, membranes were washed twice 
for 20 min in 2 X SSC/0.1% SDS at 42°C and once for 20 
min with 0.1 X SSC/0.1% SDS at 65°C. The hybridized 
mRNAs were visualized by autoradiography using Fuji FX 
film and Lightning-plus intensifiers (Kodak, Rochester, 
NY). Northern blot bands were quantified by densitometric 
scanning using a Shimadzu CS-9000 scanning densitom- 
eter (Shimadzu, Kyoto, Japan) and normalized to either 
/3-actin or GAPDH mRNA in the same sample. 
2.9. Nuclear un-on assay 
BRL). Replicate filters were fixed by ultraviolet light and 
prehybridized for at least 4 h at 42°C in a solution contain- 
ing 50% formamide, 5 X SSC, 5 X Denhardt's olution, 
and 0.1% SDS. The 32p-labeled RNA derived from each 
sample was adjusted to equivalent levels of radioactivity, 
added to the filters in fresh hybridization solution at a 
concentration of 1. l0 s cpm/ml, and incubated at 42°C 
for 40 h. The filters were washed in 2 X SSC and 0.1% 
SDS at 42°C for 30 min, and 0.1 X SSC and 0.5% SDS at 
60°C for 30 min. Filters were then exposed to X-ray film 
and quantified by Phosphorlmager analysis (Molecular 
Dynamics, Sunnyvale, CA). 
3. Resu l ts  
3.1. Suppression of porcine macrophage superoxide pro- 
duction by IL-4 
Interleukin-4 inhibits the expression of a variety of 
inflammatory cytokines, including IL-lfl, IL-8, and TNF, 
in porcine alveolar macrophages [36]. In order to deter- 
mine whether IL-4 also suppressed other macrophage in- 
flammatory activities and thus plays a general down regu- 
latory role on macrophage functions during inflammation, 
we examined the effect of IL-4 on macrophage superoxide 
production. Alveolar macrophages were isolated and cul- 
tured for 24 h in the presence or absence of various 
concentrations of IL-4 from 0 to 20 ng/ml and superoxide 
production was determined by measuring the superoxide 
dismutase-inhibitable reduction of ferricytochrome C. The 
level of superoxide production in untreated cells was ap- 
proximately 35 nmol/107 cells per 30 min, or 30 nmol/mg 
protein per h. This value is equivalent o the level of 
superoxide production previously described in porcine 
alveolar macrophages [43]. As shown in Fig. 1, IL-4 
suppressed macrophage superoxide production in a dose- 
dependent manner with a 50% reduction occurring at a 
concentration of 10 ng/ml. Maximal suppression of 70% 
was achieved at 20 ng/ml of IL-4. Thus, in addition to its 
Alveolar macrophages were cultured for 4 h in the 
presence or absence of 1 /zg/ml of LPS plus 50 ng/ml of 
recombinant human IL-4. To isolate nuclei, aliquots con- 
taining 6.107 cells were lysed in 4 ml of a solution 
containing 10 mM Tris-HCl (pH 7.4), 10 mM NaC1, 3 mM 
MgC12, and 0.5% NP-40. Nuclei were pelleted at 500 × g, 
resuspended in 200 ml of storage buffer (40% glycerol, 50 
mM Tris-HCl (pH 8.3), 5 mM MgCl2, 0.1 mM EDTA, 1 
mM DTT) and frozen in liquid N 2. Run-on transcription 
reactions were performed as described [42]. 
Approximately 5 /xg of linearized recombinant plasmid 
DNA for porcine NADPH-91 kDa subunit, NADPH-22 
kDa subunit, NADPH-47 kDa subunit, IL-lfl, TGFfll, 
human GAPDH cDNA and pGEM3Zf(+) plasmid were 
applied to nylon filters using a slot-blot apparatus (Gibco 
1(30 
80~ 
~ 4o- 
20-  
\ 
0 . . . . . .  1 . . . . .  -8 . . . . . .  - i  . . . . . .  1 . . . . . .  
0 .001  0 .01  0 . I  1 10  100  
IL-4 (ng,/ml} 
Fig. 1. Suppression of macrophage superoxide production by IL-4. 
Macrophages were cultured in 96-well plate with 105 cells/well. Cells 
were treated with various concentrations of IL-4 (0-20 ng/ml) for 24 h. 
Superoxide production was determined by measuring the superoxide 
dismutase-inhibitable reduction of ferricytochrome c. 
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suppressive ffect on inflammatory cytokine expression, 
IL-4 also suppressed superoxide production in porcine 
macrophages. 
3.2. Cloning of porcine gp91zphox cDNA 
A 1483 bp fragment of porcine gp91-phox cDNA was 
cloned by screening the porcine macrophage library with 
human gp91-phox cDNA. Sequence analysis showed that 
the first 1381 bp of this fi:agment corresponds to the 
3'-terminal part of the human gp91-phox cDNA coding 
region. An additional 376 bp fragment corresponding to 
the 5'-terminal part of human gp91-phox cDNA coding 
region was cloned by PCR. Fig. 2 shows the nucleotide 
sequence and deduced amino acid sequence of porcine 
gp91-phox cDNA (GenBank accession umber UO2476). 
The open reading frame extending from position 50 to 
1456 predicts a primary translation product of 468 amino 
acids with the estimated relative molecular mass of 54 000 
Da. Another in-frame potential translation initiator ATG 
exists at nucleotide 62. However, only the sequence flank- 
ing the ATG at position 50 resembles the consensus 
CTCAACAAGA GTTCGAAGAC AGCTGGACAG GAACCTCACC TTTCATAAAATG GTG GCG TGG 61 
M V A W 
ATG ATT GCA CTT CAC GCC ACG ATT CAC ACC ATT GCC CAT CTG TTT AAT GTG GAA 115 
M I A L H A T I H T I A H L F N V E 
TGG TGT GTG AAC GCC CGA GTC AAC AAT TCT GAC CCG TAC TCA ATA GCA CTC TCT 169 
W C V N A R V *N N S D P Y S I A L S 
GAC ATA GGA GAT AAG CCT AAT GAA ACG TAC CTC AAT TTC GTT CGA CAG AGA ATC 223 
D I G D K P *N E T Y L N F V R Q R I 
AAG AAT CCT GAA GGA GGC CTC TAC GTG GCT GTG ACT CGG CTG GCA GGC ATC ACA 277 
K N P E G G L Y V A V T R L A G I T 
GGC GTC GTC ATC ACG CTG TGT CTC ATA TTA ATT ATC ACC TCC TCC ACC AAG ACC 331 
G V V I T L C L I L I I T S S T K T 
ATC CGG AGG TCT TAC TTC GAG GTG TTC TGG TAC ACA CAC CAT CTC TTT GTG ATC 385 
I R R S Y F E V F W Y T H H L F V I 
TTC TTC ATT GGC CTT GCC ATC CAT GGA GCC GAG CGA ATT GTA CGT AGG CAG ACC 439 
F F I G L A I H G A E R I V R R Q T 
CCA AAG AGT TTG TTG GTC CAC GAT CCA AAG GCA TGT GCT CAA AAC ATC TCA CAA 493 
P K S L L V H D P K A C A Q *N I S Q 
TGG GGA AAA ATA AAG GAC TGC CCG ATC CCG GAG TTC GCA GGG AAC CCT CCT ATG 547 
W G K I K D C P I P E F A G N P P M 
ACT TGG AAA TGG ATC GTG GGT CCC ATG TTC CTG TAT CTG TGT GAG AGG CTG GTG 601 
T W K W I V G P M F L Y L C E R L V 
CGG TTT TGG CGA TCT CAG CAG AAG GTG GTC ATT ACC AAG GTG GTC ACT CAT CCT 655 
R F W R S Q Q K V V I T K V V T H P 
TTC AAA ACC ATC GAG CTA CAG ATG AAG AAG AAG GGA TTC AGG ATG GAG GTG GGA 709 
F K T I E L Q M K K K G F R M E V G 
CAA TAC ATT TTC GTC AAG CGT CCC GCA GTG TCC AAG CTG GAG TGG CAC CCT TTC 763 
Q Y I F V K R P A V S K L E W H P F 
ACC CTG ACC TCT GCC CCT GAG GAA GAC TTC TTT AGC ATC CAT ATC CGC ATT GTT 817 
T L T S A P E E D F F S I H I R I V 
GGC GAC TGG ACA GAG GGA CTG TTC AAA GCC TGT GGC TGT GAT AAG CAG GAG TTT 871 
G D W T E G L F K A C G C D K Q E F 
CAA GAT GCC TGG AAA CTA CCT AAG ATC GCT GTG GAC GGG CCC TTC GGC ACC GCC 925 
Q D A W K L P K I A V D G P F G T A 
AGT GAA GAC GTG TTC AGT TAC CAG GTG GTC ATG TTA GTG GGA GCA GGG ATT GGG 979 
S E D V F S Y Q V V M L V G A G I G 
GTC ACG CCC TTC GCC TCC ATT CTC AAG TCG GTC TGG TAC AAG TAT TGC AAT AAT 1033 
V T P F A S I L K S V W Y K Y C N *N 
GCC ACC AAT CTG AGG CTC AAA AAG ATC TAC TTC TAC TGG CTG TGC CGG GAC ACA 1087 
A T N L R L K K I Y F Y W L C R D T 
CAT GCC TTC GAG TGG TTT GCC GAC CTG CTG CAG CTG CTG GAG ACC CAG ATG CAG 1141 
H A F E W F A D L L Q L L E T Q M Q 
GAG AGG AAC AAC GCC GGC TTC CTC AGC TAC AAC ATC TAC CTC ACT GGC TGG GAT 1195 
E R N N A G F L S Y N I Y L T G W D 
GAG TCA CAG GCC AAT CAC TTT GCC GTG CAC CAT GAT GAG GAG AAA GAT GTG ATC 1249 
E S Q A N H F A V H H D E E K D V I 
ACA GGC CTG AAG CAA AAG ACC TTG TAC GGA CGG CCT AAC TGG GAT AAC GAG TTC 1303 
T G L K Q K T L Y G R P N W D N E F 
AAG ACC ArT  GCA AGT CAA CAC CCC ACT ACC AGA ATA GGA GTT TTC CTC TGC GGA 1357 
K T I A S Q H P T T R I G V F L C G 
CCG GAA GCC TTG GCT GAA ACC CTC AAT AAG CAG TGC ATC TCC AAC TCC GAC TCC 1411 
P E A L A E T L N K Q C I S N S D S 
AGC CCG AGG GGA GTG CAT TTC ATT TTC AAT AAG GAA AAC TTC TAA CCGGTCTCAT 1466 
S P R G V H F I F N K E N F Stop 
CCACGAGGA~ ATAAATGTGG GTCGTACTGC CAAATGCCCA GATAATGCCA GTTGATAATA GAAGT 1531 
TCCTT CCTTAAAAAA AAAAAAAAAA CG 1558 
Fig. 2. Nucleotide and predicted amino acid sequence of porcine gp91-phox. The nucleotide sequence was obtained from eDNA clone A90A and a 5'-end 
50 PCR fragment. The potential translation initiators ATG and ATG 62 are underlined. Four potential N-linked glycosylation sites are indicated by asterisks. 
The sequence data are deposited in GenBank (accession umber UO2476). 
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sequence for functional initiation codons defined by Kozak 
[44]. Thus the ATG at position 50 is likely the translation 
initiation codon. These two initiator ATGs are also found 
at the same positions in human gp91-phox cDNA sequence 
[45]. The deduced porcine gp91-phox contains four poten- 
tial N-linked glycosylation sites of the canonical form 
Asn-X-(Thr/Ser). Comparison of porcine and human 
gp91-phox cDNA coding regions howed a high homology 
for both nucleotide sequence (90.4%) and amino acid 
sequence (92.1%) between the two species. The calculated 
p I  of the predicted porcine gp91-phox is 8.7. Fig. 3 shows 
the comparison of the hydropathy profiles of the predicted 
porcine and human gp91-phox. Both proteins showed 
nearly identical profiles in which one extensive hydropho- 
bic segment is obvious. This segment spans amino acids 
65-92 and may represent a transmembrane domain of the 
protein. 
3.3. Suppression ofgp91-phox mRNA expression by IL-4 
To examine the molecular basis for IL-4 suppression of 
macrophage superoxide production, we determined the 
effect of IL-4 on the steady-state l vels of mRNA encod- 
ing gp91-phox and p22-phox by Northern blot analysis. 
Using the cloned porcine gp91-phox cDNA as a probe, we 
detected a single mRNA species of approximately 4.5 kb 
in macrophages with or without LPS stimulation. In these 
experiments, macrophages were cultured for 4 h with 
various concentrations of IL-4 from 0 to 100 ng/ml.  The 
results showed that IL-4 suppressed the steady-state l vels 
of gp91-phox mRNA (Fig. 4). The suppression, consistent 
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Fig. 4. Effects of IL-4 on gp91-phox and p22-phox mRNA levels. 
Macrophages were cultured for 4 h in the presence orabsence ofLPS (1 
p.g/ml) and various concentrations f IL-4 from 0 to 100 ng/ml. Total 
cellular RNA was extracted and hybridized sequentially with cDNA 
probes for gp91-phox, p22-phox, /3-actin mRNAs (A). The gp91-phox 
and p22-phox mRNA levels were quantitated bydensitometric scanning 
of hybridized bands and normalized tofl-actin mRNA levels (B). 
with the effect of IL-4 on superoxide activity, was dose- 
dependent, and maximal suppression of approximately 75% 
was detected at about 10 ng/ml  (Fig. 4B). By contrast, 
p22-phox mRNA levels were not suppressed by IL-4. 
Thus, the expression of gp91-phox and p22-phox mRNAs 
is independently regulated in macrophages and the effect 
of IL-4 is specific for gp91-phox. In addition, the mRNA 
levels of another immunosuppressive cytokine, TGFfl 1, as 
well as housekeeping genes including /3-actin and GAPDH, 
were not decreased by IL-4 (data not shown), indicating 
that the suppressive ffect of IL-4 on gp91-phox mRNA 
levels was not due to a cytotoxic effect. 
3.4. Kinetics of lL-4 suppression fmacrophage p91-phox 
mRNA expression 
To determine the time course of IL-4 suppression of 
macrophage gp91-phox mRNA expression, macrophages 
were cultured for 0-24 h with no treatment, LPS (1 
/xg/ml) alone, or with LPS and IL-4 (10 ng/ml)  added 
simultaneously. The cells were harvested at the times 
indicated in Fig. 5 for Northern blot analysis. All mRNA 
levels were normalized to GAPDH mRNA levels. Cells 
without treatment expressed readily detectable amounts of 
gp91-phox mRNA throughout the entire period of 0-24 h 
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(Fig. 5). The reduced amount at 24 h was due to less total 
RNA on the gel, as determined by staining with ethidium 
bromide and hybridization to GAPDH cDNA. LPS alone 
induced gp91-phox mRNA expression at all time points. 
Addition of IL-4, however, markedly decreased gp91-phox 
mRNA levels. The suppression occurred rapidly and was 
detected at 2 h after IL-4 addition. Maximal suppression 
was observed at 4-6 h after IL-4 addition and persisted 
throughout the entire period of 24 h. By contrast, the 
expression of p22-phox, TGF/31 and GAPDH mRNAs was 
not suppressed by IL-4 at all time points [46]. 
3.5. Interleukin-4 does not change the stability of gp91- 
phox mRNA 
In order to determine whellher the decreased gp91-phox 
mRNA levels were due to a decrease in mRNA stability, 
the rate of gp91-phox mRNA degradation i macrophages 
was examined in the presence and absence of IL-4. 
Macrophages were treated with or without IL-4 (10 ng/ml) 
for 4 h. Following the addition of 3 /zg /ml  of actinomycin 
D to block de novo synthesis of mRNA, cells were har- 
vested every hour afterwards up to 6 h. The rate of 
A. 
+LPS 
Hours After Aetinomycin D 
0 1 2 3 4 5 6 
+LPSfIL-4 g ~ ~ 
B. 
100- 
o LPS I 
- -e -  LPS/IL-4 e- 
- - -  
Z'> • ~ • • o 
* 
-1 0 1 2 3 4 5 6 7 
Hours After Actinomycin I) 
Fig. 6. Effect of IL-4 on gp91-phox mRNA stability. Macrophages were 
treated with LPS (1 p,g/ml) or LPS/IL-4 (10 ng/ml) for 4 h. Actino- 
mycin D (3 /~g/ml) was added and the cells were harvested at hourly 
intervals. Total cellular RNA was hybridized with gp91-phox eDNA and 
the mRNA levels were quantitated by densitometric s anning. 
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Fig. 5. Time-course of IL-4 suppression f gp91-phox mRNA expression. 
Maerophages were cultured for 0-24 h in the presence or absence of LPS 
(1 ~g/ml),  or LPS and IL-4 (10 ng/ml). Cells were harvested at the 
time indicated. Total cellular RNA was extracted and hybridized with 
gp91-phox and GAPDII eDNA probes sequentially (A) and gp91-phox 
mRNA levels were quantitated by densitometric s anning of hybridized 
bands and normalized to GAPDH rnRNA levels (B). 
gp91-phox mRNA degradation was measured by determin- 
ing the amount of remaining mRNA in cells as detected by 
Northern blot analysis and densitometric quantitation (Fig. 
6). The half-life of gp91-phox mRNA in cells treated with 
or without IL-4 was the same, at approximately 4 h, 
indicating that IL-4 did not affect its stability in 
macrophages. 
3.6. Effect of lL-4 on the rate of gp91-phox gene transcrip- 
tion 
Nuclear run-on assays were performed to determine if
gp91-phox expression was induced at the transcriptional 
level. Nuclei were isolated from resting macrophages and 
from cells treated with LPS (1 /zg/ml), IL-4 (50 ng/ml) 
or both for 4 h. Transcripts were extended in vitro with the 
incorporation of [32p]UTP and hybridized to a panel of 
plasmid clones that included gp91-phox, p22-phox, p47- 
phox, IL-1 fl, TGF/31, GAPDH, and pGEM3Zf( + ) vector 
alone. The results show that LPS and IL-4 neither in- 
creased nor decreased the rate of transcription of any of 
the genes analyzed except for IL-1/3 (Fig. 7). Phosphorim- 
ager analysis howed less than a 2.5-fold difference in the 
amount of radioactivity in samples from the NADPH 
oxidase subunit genes, TGF/3 1 and GAPDH regardless of 
treatment. The only effect of IL-4 on transcription was to 
suppress by more than 80% the induction of IL-1/3 by 
LPS. Hence, the effect of IL-4 on mRNA levels of gp91- 
phox appears to be post-transcriptional, perhaps at the 
level of mRNA processing. 
46 Y. Zhou et al. / Biochimica et Biophysica Acta 1265 U995) 40-48 
÷ 
gp91-phox 
p22-phox 
p47-phox ;~ 
TGFB1 
GAPDH ~ ~ ~ 
pGEMSZf(+) - • 
Fig. 7. Effect of IL-4 on gp91-phox transcription. Nuclei were isolated 
from cells treated with LPS (1 /.~g/ml), IL-4 (50 ng/ml),  both or neither 
for 4 h. Nuclear run-on assays were performed as described in Section 2. 
Labeled transcripts were hybridized to the indicated cDNAs and visual- 
ized by autoradiography. 
3.7. Effect of TGFfll on porcine macrophage superoxide 
production and NAPDH oxidase gene expression 
To investigate whether the suppression of superoxide 
production and NADPH oxidase xpression was a specific 
response of macrophages to IL-4, the effect of IL-4 was 
compared with another immunosuppressive cytokine, 
TGF/31, on macrophage superoxide production and 
NADPH oxidase gene expression. Macrophages were cul- 
tured for 6 h with 10 ng/ml of TGF/31, 10 ng/ml of IL-4, 
or neither. Superoxide production and gp91-phox mRNA 
levels were determined by superoxide assay and Northern 
blot, respectively, and expressed as percent of control for 
comparison. Superoxide anion production i  untreated cells 
varied from 30 to 50 nmol  O2/10  7 cells/30 min. As 
shown in Table 1, IL-4 significantly decreased superoxide 
production and gp91-phox mRNA levels to 32 5: 2% and 
26 5: 6%, respectively. However, superoxide production 
and gp91-phox mRNA levels remained unchanged at 101 
Table 1 
Comparison of the effect of TGFfl 1 and IL-4 on suppression of superox- 
ide production and gp91-phox gene expression 
Treatment Superoxide gp91-phox 
anion a mRNA b 
None 100 100 
TGFfl l  (10 ng/ml)  101 -t-3 102+ 11 
IL-4 (10 ng/ml)  32 + 2 26 + 6 
a Cells were cultured for 24 h with or without TGF/31 or IL-4. The 
superoxide production was determined by measuring the superoxide 
dismutase-inhibitable reduction of ferricytochrome C. Results are ex- 
pressed as the percent of control. 
b Cells were cultured in the presence or absence of TGFfl 1 or I1..4 for 6 h. 
Total cellular RNA was hybridized sequentially with probes for gp91- 
phox, GAPDH or/3-actin. The gp91-phox mRNA levels were determined 
by densitometdc scanning, normalized to GAPDH or /3-actin and ex- 
pressed as percent of control. 
+ 3% and 102 _ 10%, respectively, in cells treated with 
TGFfl 1. 
4. Discussion 
Interleukin-4, originally characterized as a B-cell growth 
factor, also possesses anti-inflammatory effects on human 
and mouse monocytes and macrophages [31-35]. In porcine 
alveolar macrophages, IL-4 suppressed the production of 
inflammatory cytokines, including IL-la, IL-lfl, TNFa 
and IL-8, by suppressing the level of transcription of the 
genes [36]. Here, we demonstrated that IL-4, in addition to 
the suppression of macrophage inflammatory cytokine x- 
pression, also suppressed superoxide production i  porcine 
alveolar macrophages, but at a posttranscriptional level. 
The results from porcine alveolar macrophages are consis- 
tent with other observations that IL-4 suppressed superox- 
ide production from human and murine macrophages [47- 
50]. These observations indicate that IL-4 plays an active 
role in regulating macrophage inflammatory activities. 
The effect of IL-4 on production of superoxide anion is 
due to the suppression of NADPH oxidase activity by IL-4 
which is specific for gp91-phox. The p22-phox mRNA 
levels were not altered by IL-4, indicating that the mRNAs 
encoding these two subunits are regulated independently in
porcine macrophages. Similar observations, in which the 
91 kDa mRNA was strikingly regulated but 22 kDa mRNA 
remained unchanged under the same conditions, was re- 
ported previously [7,10,11,51]. This differential regulation, 
together with the observations that gp91-phox mRNA is 
only expressed in cells of the phagocytic lineage whereas 
stable mRNA encoding p22-phox is expressed in all cell 
types [51], suggests an important catalytic role of gp91- 
phox in generating superoxide anion in phagocytes. 
Comparison of human and porcine gp91-phox cDNA 
and amino acid sequences showed a very high degree of 
similarity between these two species in their nucleotide 
and amino acid sequences as well as their hydropathy 
profile. The original cloning of human gp91-phox cDNA 
defined a translation initiator ATG at nucleotide position 
322 [45]. However, subsequent purification and sequencing 
of gp91-phox identified another 43 amino acids whose 
nucleotide sequence corresponds to the originally desig- 
nated non-coding region 5' to the initiator ATG 32z [52]. 
The initiation codon ATG at nucleotide position 50 in the 
cloned porcine gp91-phox cDNA corresponds to the hu- 
man gp91-phox initiation codon ATG 322. Since the pre- 
dicted molecular mass of the porcine and human gp91-phox 
are both about 54 kDa, it is possible that cloned cDNAs 
may not represent the entire coding region of the protein, 
or that the mature proteins are posttranslationally modified 
by glycosylation. 
The gp91-phox mRNA is present in unstimulated 
porcine macrophages, and is induced by LPS, similar to 
other reports [7-9,11,12]. Both constitutive and LPS-in- 
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duced gp91-phox mRNA expression were suppressed by 
IL-4, indicating that the IL-4 suppression is a direct effect 
on gp91-phox mRNA rather tlhan secondary to an effect on 
LPS responsiveness. The stability of gp91-phox mRNA 
was not changed by IL-4, similar to the results observed 
for inflammatory c tokines. Although IL-4 suppression of 
macrophage inflammatory cytokine mRNA expression oc- 
curred at the transcriptional level [36], and others have 
reported that the regulation of gp91-phox and p47-phox 
mRNA expression by IFN3, is a transcriptional event 
[8,10], it appears that IL-4 suppressed gp91-phox mRNA 
levels posttranscriptionally, perhaps by reducing the effi- 
ciency of its transcriptional processing. 
Several other cytokines, in addition to IL-4, have also 
been shown to possess immunosuppressive or anti-in- 
flammatory activities. In particular, TGFfl inhibits the 
induction of IL-lfl and TNFa by LPS in human periph- 
eral blood mononuclear cells [53] and suppresses superox- 
ide production in human macrophages [54]. However, we 
did not observe the suppressive effect of TGF/31 on either 
superoxide production or gp91-phox mRNA expression i  
porcine alveolar macrophages. One possibility for this 
discrepancy in TGFfl effect on macrophage superoxide 
production detected by us and others is due to different 
experimental conditions and ,different species. In addition, 
IL-4 had no effect on TGF/3 mRNA expression (data not 
shown), indicating that IL-4 suppression is not mediated 
through TGF]3 activity. Interleukin-10 and IL-13, cy- 
tokines produced by T H 2 cells, are active in suppression of 
macrophage inflammatory cytokine production, including 
IL- la,  IL-lfl, IL-6, IL-8 and TNFt~ [55-57] or have 
activities imilar to IL-4 [58],. respectively. However, their 
effects on macrophage superoxide production are not 
known. 
An increasing body of evidence suggests that oxygen 
metabolites are capable of causing injury to various cells 
and tissues and mediating inflammatory diseases when 
overproduced [13-28]. Thus, it appears that, for a produc- 
tive immune response to acute infection appropriate limita- 
tion of inflammatory activity, including superoxide produc- 
tion, is necessary in order to limit host damage after the 
primary pathogenic nsult has; been blunted. The limitation 
of macrophage superoxide production can be achieved 
through both exogenous treatment with inhibitors of reac- 
tive oxygen intermediates and endogenous induction of 
immunosuppressive modulators. It has been reported that 
local injection of superoxide dismutase is beneficial in the 
treatment of rheumatoid arthritis and other inflammatory 
diseases [19,59-61]. A recent study also showed that 
intraarticular injection of SOD or catalase significantly 
reduced the group A streptococcal cell wall-induced in- 
flammatory response and evolution of erosive arthritis in a 
rat model [15]. In vivo studies with administration of 
recombinant IL-4 as an imraunotherapeutic agent to pa- 
tients with renal cell carcinoma or malignant melanoma 
showed that monocytes frorn post-therapy patients exhib- 
ited reduced production of superoxide anion [50]. Although 
exogenous ubstances are beneficial in the treatment of 
inflammatory diseases, a more efficient strategy would be 
the induction of endogenous immunosuppressive modula- 
tors. Our results suggested that IL-4 may be a candidate 
immunomodulator which acts in vivo to suppress uperox- 
ide production and thus prevent undue damage from the 
inflammatory eaction to pathogens. 
Acknowledgements 
We would like to thank Dr. William A. Toscano (Tulane 
University, New Orleans, LA) for providing human 
GAPDH cDNA and Dr. Stephen Chanock (The Children's 
Hospital, Boston, MA) for providing the human gp91-phox 
cDNA. 
References 
[1] Segal, A.W. (1989) J. Clin. Invest. 83, 1785-1793. 
[2] Segal, A.W. and Jones, O.T.G. (1978) Nature 276, 515-517. 
[3] Cross, A.R. and Jones, O.T.G. (1991) Biochim. Biophys. Acta 1057, 
281-298. 
[4] Parkos, C.A., Allen, R., Cochrane, C. and Jesaitis, A. (1987) J. Clin. 
Invest. 80, 732-742. 
[5] Segal, A.W. (1987) Nature 326, 88-91. 
[6] Macphail, L.C., Clayton, C.C, and Snyderman, R. (1984) J. Biol. 
Chem. 259, 5768-5775. 
[7] Cassatella, M.A., Bazzoni, F., Flynn, R.M., Dusi, S., Trinchieri, G. 
and Rossi, F. (1990) J. Biol Chem. 265, 20241-20246. 
[8] Newburger, P.E., Ezekowitz, R.A.B., Whitney, C., Wright, J. and 
Orkin, S.H. (1988) Proc. Natl. Acad. Sci. USA 85, 5212-5219. 
[9] Amezaga, M.A., Bazzoni, F., Sorio, C., Rossi, F. and Cassateila, 
M.A. (1992) Blood. 79, 735-744. 
[10] Cassatella, M.A., Bazzoni, F., Calzetti, F., Guasparri, I., Rossi, F. 
and Trinchieri, G. (1991) J. Biol. Chem. 266, 22079-22082. 
[11] Cassatella M.A., Hartman, L., Perussia, B. and Trinchieri, G. (1989) 
J. Clin. Invest. 83, 1570-1579. 
[12] Gupta, J.W., Kubin, M., Hartman. L., Cassatella, M. and Trinchieri, 
G. (1992) Cancer Res. 52, 2530-2537. 
[13] HalliweU, B. (1987) FASEB J. 1, 358-364. 
[14] Halliwell, B. (1982) Cell Biol. Int. Rep. 6, 529-539. 
[15] Skaleric, U., Allen, J.B., Smith, P.D., Mergenhagen, S.E. and Wahl, 
S.M. (1991) J. Immunol. 147, 2559-2564. 
[16] Kasama, T., Kobayashi, K., Fukushima, T., Tabata, M., Ohno, I., 
Negishi, M., Ide, H., Takahashi, T. and Niwa, Y. (1989) Clin. 
Immunol. Immunopathol. 53, 439-448. 
[17] Kato, M., Morikawa, A., Kimura, H., Shimizu, T., Nakano, M. and 
Knroume, T. (1991) Int. Arch. Allergy Appl. Immunol. 96, 128-133. 
[18] Shasby, D.M., Vanbenthuysen, K.M., Tate, R.M., Shasby, S.S., 
McMurtry, I. and Repine, J.E. (1981) Am. Rev. Respir. Dis. 125, 
443-447. 
[19] Petrone, W.F., English, D.K., Wong, K. and McCord, J.M. (1980) 
Proc. Natl. Acad. Sci. USA 77, 1159-1163. 
[20] Sachs, T.C., Moldow, C.F., Craddock, P.R., Bowers, J.K. and 
Jacobs, H.S. (1978) J. Clin. Invest. 61, 1161-1167. 
[21] Kato, M., Nakano, M., Morikawa, A., Kimura, H., Shigeta, M. and 
Kuroume, T. (1991) Int. Arch. Allergy Appl. Immunol. 95, 17-22. 
[22] Mulder, T.J.P., Verspaget, H.W., Janssens, A.R., De Bruin, P.A.F., 
Pena, A.S. and Lamers, C.B.H.W. (1991) Gut 32, 1146-1150. 
48 Y. Zhou et al. / Biochimica et Biophysica Acta 1265 (1995) 40-48 
[23] Neuschwander-Tetri, B.A., Ferrell, L.D., Sukhabote, R.J. and Gren- 
dell, J.H. (1992) J. Clin. Invest. 89, 109-116. 
[24] Andreoli, S.P. (1991) Pediatr. Nephrol. 5, 733-742. 
[25] Trenam, C.W., Dabbagh, A.J., Morris, C.J. and Blake, D.R. (1991) 
Br. J. Dermatol. 125, 325-329. 
[26] Taoka, H. (1991) Gastroenterol. Jpn. 26, 633-644. 
[27] Gritz, D.C., Montes, C., Atalla, L.R., Wu, G.S., Sevanian, A. and 
Rao, N.A. (1991) Curr. Eye Res. 10, 927-931. 
[28] Kimura, T., Kameoka, M. and Ikuta, K. (1993) FEBS Lett. 326, 
232-236. 
[29] Howard, M., Farrar, J., Hilfilker, M., Johnson, B., Takatsu, K., 
Hamaoka, T. and Pan, W.E. (1982) J. Exp. Med. 155, 914-923. 
[30] Mosmann, T.R., Cherwinski, H., Bond, M.W., Giedlin, M.A. and 
Coffman, R.L. (1986) J. Immunol. 136, 2348-2357. 
[31] Donnelly, R.P., Fenton, M.J., Finbloom, D.S. and Gerrard, T.L. 
(1990) J. Immunol. 145, 569-575. 
[32] Hart, P.H., Vitti, G.F., Burgess, D.R., Whitty, G.A., Piccoli, D.S. 
and Hamilton, J.A. (1989) Proc. Natl. Acad. Sci. USA 86, 3803- 
3807. 
[33] Kunkel, S.L., Standiford, T., Kasahara, K. and Stricter, R.M. (1991) 
Exp. Lung Res. 17, 17-23. 
[34] Standiford, T.J., Strieter, R.M., Chensue, S.W., Westwick, J., Kasa- 
hara, K. and Kunkel, S.L. (1990) J. Immunol. 145, 1435-1439. 
[35] Te Velde, A.A., Huijbens, R.J.F., Heije, K., De Vries, J.E. and 
Figdor, C.G. (1990) Blood 76, 1392-1397. 
[36] Zhou, Y., Lin, G., Baarsch, M.J., Scamurra, R.W., and Murtaugh, 
M.P. (1994) J. Leukoc. Biol. 56, 507-513. 
[37] Sanger, F., Nicklen, S. and Coulson, A.R. (1977) Proc. Natl. Acad. 
Sci. USA 74, 5463-5467. 
[38] Peterson, P.K., Sharp, B., Gekker, G., Brummitt, C. and Keane, 
W.F. (1987) J. Immunol. 138, 3907-3912. 
[39] Pick, E. and Mizel, D. (1981) J. Immunol. Methods 46, 211-226. 
[40] Chomczynski, P. and Sacchi, N. (1987) Anal. Biochem. 162, 156- 
159. 
[41] Sambrook, J., Fritsch, E.F. and Maniatis, T. (1989) Molecular 
Cloning: A Laboratory Manual, 2nd Edn., Cold Spring Harbor 
Laboratory. Cold Spring Harbor, New York. 
[42] Lin, G., Pearson, A.E., Scamurra, R.W., Zhou, Y., Baarsch, M.J., 
Weiss, D.J., and Murtaugh, M.P. (1994) J. Biol. Chem. 269, 77-85. 
[43] Edwards III, C.K., Ghiasuddin, S.M., Schepper, J.M. Yunger, L.M., 
and Kelley, K.W. (1988) Science 239, 769-771. 
[44] Kozak, M. (1987) J. Mol. Biol. 196, 947-950. 
[45] Royer-Pokora, B., Kunkel, L.M., Monaco, A.P., Goff, S.C., New- 
burger, P.E., Baehner, R.L., Cole, F.S., Curnutte, J.T. and Orkin, 
S.H. (1986) Nature 322, 32-38. 
[46] Zhou, Y. and Murtaugh, M.P. (1994) Gene, 148, 363-367. 
[47] Appelberg, R., Orme, I.M., Pinto De Sousa, M.I. and Silva, M.T. 
(1992) Immunol. 76, 553-559. 
[48] Bhaskaran, G., Nii, A., Sone, S. and Ogura, T. (1992) J. Leukoc. 
Biol. 52, 218-223. 
[49] Ho, J.L., He, S.H., Rios, M.J.C. and Wick, E.A. (1992) J. Infect. 
Dis. 165, 344-351. 
[50] Wong, H.L., Lotze, M.T., Wahl, L.M. and Wahl, S.M. (1992) J. 
Immunol. 148, 2118-2125. 
[51] Parkos, C.A., Dinauer, M.C., Walker, L.E., Allen, R.A., Jesaitis, 
A.J. and Orkin, S.H. (1988) Proc. Natl. Acad. Sci. USA 85, 3319- 
3323. 
[52] Teahan, C., Rowe, P., Parker, P., Totty, N. and Segal A.W. (1987) 
Nature 327, 720-721. 
[53] Chantry, D., Turner, M., Abney, E. and Feldmann, M. (1989) J. 
Immunol. 142, 4295-4300. 
[54] Tsunawaki, S., Sporn, M., Ding, A. and Nathan, C. (1988) Nature 
334, 260-262. 
[55] Bogdan, C., Vodovotz, Y. and Nathan, C. (1991) J. Exp. Med. 174, 
1549-1555. 
[56] De Waal Malefy, R., Abrams, J., Bennett, B., Figdor, C.G. and De 
Vries, J.E. (1991) J. Exp. Med. 174, 1209-1220. 
[57] Fiorentino, D.F., Zlotnik, A., Mosmanu, T.R., Howard, M. and 
O'Garra, A. (1991) J. Immunol. 147, 3815-3822. 
[58] Minty, A., Chalon, P., Derocq, J.M., Dumont, X., Guillemot, J.C., 
Kaghad, M., Labit, C., Leplatois, P., Liauzun, P., Miloux, B., Minty, 
C., Casellas, P., Loison, G., Lupker, J., Shire, D., Ferrara, P. and 
Caput, D. (1993) Nature 362, 248-250. 
[59] Goebel, K.M. and Storck, U. (1983) Am. J. Med. 74, 124-128. 
[60] Goebel, K.M., Storck, U. and Neurath, F. (1981) Lancet 1, 1015- 
1017. 
[61] Menander-Huber, K.B. (1981) J. Rheumatol. Inflam. 4, 201-211. 
